Find the product you need

News

Fetuin-A (AHSG) Human ELISA

Catalog number: RD191037100
Brand: BioVendor
Packing: 96 wells
Price: € 482.00
Expected delivery time: 7 days
Quantity:
Spin UpSpin Down

Product specifications for - Fetuin-A (AHSG) Human ELISA

Overview: 
Product group: Assays
Category: ELISA / EIA
Properties: 
Molecular weight: 59 kDa
Assay Sensitivity: 0,104 ng/ml
Assay Precision: Inter assay: n = 6, CV = 4,7%, Intra assay: n = 8, CV = 2,9%,
Assay Sample Type: serum and plasma (EDTA, citrate, heparin)
Assay Time: The total assay time is less than 3 hours
Assay Detection Range: 2 - 100 ng/ml
  IVD Certification
UNSPSC: 41116158
Storage instructions: Store the kit at 2-8-¦C. Under these conditions, the kit is stable until the expiration date (see label on the box).
Scientific information: 
Scientific info: Fetuin-A (AHSG), a 59 kDa glycoprotein, consists of two cystatin-like domains and a smaller unrelated domain. Its homologues have been identified in several species including rat (pp63), mouse, guinea pig, rabbit, sheep, cattle, swine and human. AHSG human gene is located on chromosome 3q27. Liver synthesized fetuin-A is secreted into the blood stream and it is deposited as a noncollagenous protein in mineralized bones and teeth. Fetuin-A occurs in high serum concentration during fetal life, whereas its level declines following infection, inflammation (by 20-30% during acute phase) and malignancy. Fetuin-A may influence the resolution of inflammation by modulating the phagocytosis of apoptotic cells by macrophages. Fetuin-A acts as an important circulating inhibitor of ectopic calcification that is a frequent complication of many degenerative diseases. The low fetuin-A level may be associated with higher cardiovascular mortality in chronic renal failure, liver cancer and liver cirrhosis patients on long-term dialysis. Human fetuin-A represents a natural inhibitor of tyrosine kinase activity of the insulin receptor. Fetuin-A may play a significant role in regulating postprandial glucose disposal, insulin sensitivity, weight gain, and fat accumulation and may be a novel therapeutic target in the treatment of type 2 diabetes, obesity, and other insulin-resistant conditions. The serum and bone-resident fetuin-A binds to transforming growth factor-beta and blocks TGF-beta binding to cell surface receptors. Thus, fetuin-A is involved at least in inhibition of unwanted (vascular) calcification, inhibition of insulin receptor tyrosine kinase activity and regulation of osteogenesis.
Additional information: 
Synonyms: RD191037100; BioVendor
Abali R, Celik C, Tasdemir N, Guzel S, Alpsoy S, Yuksel A, Celik E. The serum protein alpha2-Heremans-Schmid glycoprotein/fetuin-a concentration and carotid intima-media thickness in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Bi. 2013 Jul,169 (1):45-9 Read more
Aleksandrova K, Giuseppe RD, Isermann B, Biemann R, Schulze MB, Wittenbecher C, Fritsche A, Lehmann R, Menzel J, Weikert C, Pischon T, Boeing H. Circulating Omentin as a Novel Biomarker for Colorectal Cancer Risk: Data from the EPIC Potsdam Cohort Study. Cancer Res. 2016 May 23 Read more
Argani H, Ghorbanihaghjo A, Panahi G, Rashtchizadeh N, Safa J, Meimand SM. Serum Fetuin-A and Pentraxin3 in hemodialysis and renal transplant patients. Clin Biochem. 2012 Jul,45 (10-11):775-9 Read more
Bakiner O, Bozkirli E, Ertugrul D, Sezgin N, Ertorer E. Plasma fetuin-A levels are reduced in patients with hypothyroidism. Eur J Endocrinol. 2014 Mar,170 (3):411-8 Read more
Blaha V, Mistrik E, Dusilova-Sulkova S, Kalousova M, Andrys C, Blaha M, Sobotka L. Circulating fetuin-A predicts early mortality in chronic hemodialysis patients. Clin Biochem. 2009 Jul,42 (10-11):996-1000 Read more
Brettschneider J, Lehmensiek V, Mogel H, Pfeifle M, Dorst J, Hendrich C, Ludolph AC, Tumani H. Proteome analysis reveals candidate markers of disease progression in amyotrophic lateral sclerosis (ALS). Neurosci Lett. 2010 Jan 1,468 (1):23-7 Read more
Briana DD, Boutsikou M, Gourgiotis D, Boutsikou T, Baka S, Marmarinos A, Hassiakos D, Malamitsi-Puchner A. Serum fetuin-A/alpha2-HS-glycoprotein in human pregnancies with normal and restricted fetal growth. J Matern Fetal Neonatal Med. 2008 Nov,21 (11):826-30 Read more
Brix JM, Stingl H, Hollerl F, Schernthaner GH, Kopp HP, Schernthaner G. Elevated Fetuin-A concentrations in morbid obesity decrease after dramatic weight loss. J Clin Endocrinol Metab. 2010 Nov,95 (11):4877-81 Read more
Caglar K, Yilmaz MI, Saglam M, Cakir E, Acikel C, Eyileten T, Yenicesu M, Oguz Y, Vural A, Carrero JJ, Axelsson J, Lindholm B, Stenvinkel P. Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol. 2008 Jan,3 (1):61-8 Read more
Caglar K, Yilmaz MI, Saglam M, Cakir E, Kilic S, Sonmez A, Eyileten T, Yenicesu M, Oguz Y, Tasar M, Vural A, Ikizler TA, Stenvinkel P, Lindholm B. Serum fetuin-a concentration and endothelial dysfunction in chronic kidney disease. Nephron Clin Pract. 2008,108 (3):c233-40 Read more